SAN JOSE, Calif., Aug. 24, 2020 (GLOBE NEWSWIRE) -- AnPac Bio-Medical Science Co., Ltd. ("AnPac Bio," the "Company" or "we") (NASDAQ:ANPC), a biotechnology company with operations in China and the United States announced today that the company received a certificate of registration this month under the U.S. Clinical Laboratory Improvement Amendmentsof 1988, or CLIA, for its approximately 7,000 square foot lab in Philadelphia, Pennsylvania. The AnPac Bio Philadelphia lab is dedicated to cancer differentiation analysis (CDA) liquid biopsy research as well as various other commercial diagnostic testing.
Dr. Chris Yu, AnPac Bio's Chairman and CEO commented: "We are very pleased about the CLIA registration for our laboratory in Philadelphia, Pennsylvania.We plan to continue our research and commercialize our CDA technology for cancer risk assessment as well as perform other commercial diagnostic tests in our Philadelphia lab, including COVID-19 antibody testing. We are fully committed to innovation and commercialization in the United States. The CLIA registration of our Philadelphia lab is a testimony that we adhere to the highest standards in the industry, and it is a major milestone towards our commercialization in the U.S."